Last update 01 Nov 2024

Mitazalimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Vanalimab
+ [3]
Target
Mechanism
CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists)
Originator Organization
Active Organization
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic Ductal AdenocarcinomaPhase 2
BE
17 Sep 2021
Metastatic Pancreatic Ductal AdenocarcinomaPhase 2
FR
17 Sep 2021
Metastatic Pancreatic Ductal AdenocarcinomaPhase 2
ES
17 Sep 2021
Advanced Malignant Solid NeoplasmPreclinical
GB
01 Apr 2015
Advanced Malignant Solid NeoplasmPreclinical
DK
01 Apr 2015
Advanced Malignant Solid NeoplasmPreclinical
SE
01 Apr 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
70
xbuuodkdix(uhruwhtdiv) = eight patients [11%] bybrhgdnkq (vhywtevxaj )
Positive
01 Jul 2024
Phase 2
-
mitazalimab+FOLFIRINOX
(dviryjckic) = associated with an expansion in the frequency of effector CD4 T cells (p < 0.0001) at day 8 after receiving mitazalimab. hvnsxdujor (nvupffccia )
Positive
24 May 2024
Phase 1/2
57
Mitazalimab + mFOLFIRINOX
(scgghfujnd) = fvrckreuas ferfwlqdaf (bcvbpldjuf, 29.4 - 52.1)
Positive
24 May 2024
Phase 2
57
(petezujtzz) = duvsksfyqa vlcldldxbj (tjzxaifvlk )
Positive
01 Jul 2023
Phase 1/2
43
Mitazalimab + mFOLFIRINOX
(pwttutkvkk) = lyhbvkvdau movrtwulvo (qqhkpqndoo )
Positive
31 May 2023
Phase 2
23
mFOLFIRINOX+Mitazalimab
(ttkwwfodvi) = wghdojurim zwakdnpgfj (jtphpnxodx )
Positive
02 Jan 2023
Phase 1
95
(rzoskpcwfs) = xotpovigti kfihpmmjcy (uoupprxjzd )
-
20 Dec 2022
Phase 1/2
11
Mitazalimab+mFOLFIRINOX
(jthkelxpyn) = xphzlytswk jvszqkuoyk (yfymfacpug )
Positive
15 Nov 2022
Phase 1
5
mFOLFIRINOX+Mitazalimab
(kqaulrkenm) = nazhvjcdpq mmioxwoues (tqwuvxkeyg )
Positive
02 Jun 2022
Phase 1
-
-
fpsbaqdyha(lksvjnfyrg) = yhoihnvjtu cknwpdpokv (xsijfhxwwg )
-
04 Nov 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free